Crossmark Global Holdings, Inc. Vertex Pharmaceuticals Inc Transaction History

Crossmark Global Holdings, Inc.

$5.49 Billion
Q4 2024

A detailed history of Crossmark Global Holdings, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 6,207 shares of VRTX stock, worth $2.99 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

6,207

Previous 5,866 5.81%

Holding current value

$2.99 Million

Previous $2.73 Million 8.43%

% of portfolio

0.05%

Previous 0.05%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 16, 2025	BUY	$396.64 - $516.74 $135,254 - $176,208	341 Added 5.81%	6,207 $2.5 Million
Q3 2024 Nov 04, 2024	SELL	$460.0 - $505.78 $137,080 - $150,722	-298 Reduced 4.83%	5,866 $2.73 Million
Q2 2024 Jul 29, 2024	SELL	$392.81 - $485.53 $13,355 - $16,508	-34 Reduced 0.55%	6,164 $2.89 Million
Q1 2024 May 13, 2024	SELL	$407.69 - $446.08 $934,017 - $1.02 Million	-2,291 Reduced 26.99%	6,198 $2.59 Million
Q4 2023 Feb 13, 2024	BUY	$343.0 - $410.68 $157,780 - $188,912	460 Added 5.73%	8,489 $3.45 Million
Q3 2023 Nov 08, 2023	BUY	$338.18 - $362.46 $428,474 - $459,236	1,267 Added 18.74%	8,029 $2.9 Million
Q2 2023 Jul 31, 2023	BUY	$314.42 - $351.91 $26,411 - $29,560	84 Added 1.26%	6,762 $2.39 Million
Q1 2023 May 12, 2023	SELL	$283.23 - $323.1 $809,754 - $923,742	-2,859 Reduced 29.98%	6,678 $2.1 Million
Q4 2022 Jan 19, 2023	BUY	$285.76 - $321.48 $117,161 - $131,806	410 Added 4.49%	9,537 $2.75 Million
Q3 2022 Nov 01, 2022	BUY	$273.83 - $305.53 $101,590 - $113,351	371 Added 4.24%	9,127 $2.64 Million
Q2 2022 Jul 29, 2022	SELL	$234.96 - $292.55 $59,209 - $73,722	-252 Reduced 2.8%	8,756 $2.47 Million
Q1 2022 May 11, 2022	BUY	$221.42 - $260.97 $280,539 - $330,648	1,267 Added 16.37%	9,008 $2.35 Million
Q4 2021 Jan 10, 2022	SELL	$177.01 - $223.45 $37,172 - $46,924	-210 Reduced 2.64%	7,741 $1.7 Million
Q3 2021 Oct 21, 2021	SELL	$181.39 - $202.99 $28,841 - $32,275	-159 Reduced 1.96%	7,951 $1.44 Million
Q3 2021 Oct 13, 2021	BUY	$181.39 - $202.99 $31,561 - $35,320	174 Added 2.19%	8,110 $453,000
Q2 2021 Jul 21, 2021	SELL	$187.49 - $221.1 $190,302 - $224,416	-1,015 Reduced 11.34%	7,936 $1.6 Million
Q1 2021 Apr 15, 2021	SELL	$207.02 - $241.31 $74,527 - $86,871	-360 Reduced 3.87%	8,951 $1.92 Million
Q4 2020 Jan 14, 2021	SELL	$207.01 - $276.09 $91,705 - $122,307	-443 Reduced 4.54%	9,311 $2.2 Million
Q3 2020 Oct 08, 2020	SELL	$255.65 - $303.1 $3.89 Million - $4.61 Million	-15,207 Reduced 60.92%	9,754 $2.65 Million
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $278,918 - $365,904	1,237 Added 5.21%	24,961 $7.25 Million
Q1 2020 Apr 28, 2020	BUY	$199.77 - $247.81 $47,145 - $58,483	236 Added 1.0%	23,724 $5.65 Million
Q4 2019 Feb 06, 2020	SELL	$166.71 - $223.91 $583,985 - $784,356	-3,503 Reduced 12.98%	23,488 $5.14 Million
Q3 2019 Oct 09, 2019	BUY	$166.23 - $187.09 $6,482 - $7,296	39 Added 0.14%	26,991 $4.57 Million
Q2 2019 Jul 09, 2019	BUY	$164.61 - $190.37 $76,379 - $88,331	464 Added 1.75%	26,952 $4.94 Million
Q1 2019 May 02, 2019	SELL	$163.73 - $194.7 $65,328 - $77,685	-399 Reduced 1.48%	26,488 $4.87 Million
Q4 2018 Jan 31, 2019	SELL	$151.91 - $192.21 $211,306 - $267,364	-1,391 Reduced 4.92%	26,887 $4.46 Million
Q3 2018 Nov 08, 2018	SELL	$167.73 - $192.74 $170,078 - $195,438	-1,014 Reduced 3.46%	28,278 $5.45 Million
Q2 2018 Jul 31, 2018	SELL	$145.72 - $169.96 $115,118 - $134,268	-790 Reduced 2.63%	29,292 $4.98 Million
Q1 2018 Apr 16, 2018	SELL	$151.6 - $177.13 $380,970 - $445,127	-2,513 Reduced 7.71%	30,082 $4.9 Million
Q4 2017 Feb 05, 2018	BUY	$137.28 - $155.55 $1.39 Million - $1.58 Million	10,135 Added 45.12%	32,595 $4.89 Million
Q3 2016 Oct 25, 2017	BUY	N/A	22,460	22,460 $3.42 Million

Others Institutions Holding VRTX

# of Institutions

1,715

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $124B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.

Account

Crossmark Global Holdings, Inc. Vertex Pharmaceuticals Inc Transaction History